Search Results
Your search for ,AnY matches 8157 pages
Showing 2051 - 2100Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment
In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving active cancer treatment. Antibody levels prior to and...
Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
In a pooled analysis of individual patient data from trials in the U.S. Food and Drug Administration database reported in JAMA Oncology, Anscher et al found that patients with cancer receiving radiotherapy within 90 days prior to the start of immune checkpoint inhibitor treatment were not at...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma
In the phase II/III RELATIVITY-047 trial reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, to nivolumab, a PD-1 inhibitor, significantly prolonged...
Be Realistic About What Patients Can Expect After Prostate Cancer Treatment
More than 1 in 10 patients with localized prostate cancer experienced treatment-related regret, a study published in JAMA Oncology suggests. And the major driver of that regret seems to be a disconnect between patient expectations and outcomes.1 In an interview with The ASCO Post, the study’s lead...
Does Armodafinil Improve Cancer-Related Fatigue in Patients With High-Grade Glioma?
In a phase III trial reported in JAMA Oncology, Porter et al found that armodafinil, a psychostimulant, did not improve cancer-related fatigue vs placebo in adult patients with high-grade glioma. As stated by the investigators, “Nearly 96% of patients with high-grade glioma report...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory B-Cell Lymphomas
In a phase I study reported in the Journal of Clinical Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that the CD20-CD3 bispecific antibody mosunetuzumab produced durable responses in patients with relapsed or refractory aggressive and indolent B-cell non-Hodgkin lymphomas....
Pretreatment Disease Burden and Outcomes With Commercial Tisagenlecleucel in Pediatric/Young Adult B-Cell ALL
In an analysis from the Pediatric Real-World Chimeric Antigen Receptor Consortium reported in the Journal of Clinical Oncology, Schultz et al found that pretreatment high disease burden was associated with poorer outcomes in pediatric and young adult patients who received commercial...
NCCN Updates Recommendations on COVID-19 Vaccination and Preexposure Prophylaxis
Today, the National Comprehensive Cancer Network® (NCCN®) published significant updates to the expert consensus recommendations on vaccination and preexposure prophylaxis of COVID-19 for people with cancer. The NCCN Advisory Committee on COVID-19 Vaccination and Preexposure Prophylaxis meets...
Association of Response Rate and Event-Free Survival With Overall Survival in Newly Diagnosed AML: FDA Analysis
In a trial-level analysis of randomized studies submitted to the U.S. Food and Drug Administration (FDA) reported in the Journal of Clinical Oncology, Norsworthy et al found that complete remission rate was moderately correlated, and event-free survival was strongly correlated, with overall...
Polatuzumab Vedotin-piiq Plus R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL
In the phase III POLARIX trial reported in The New England Journal of Medicine, Tilly et al found that polatuzumab vedotin-piiq plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) significantly improved progression-free survival vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...
Second-Line Tisagenlecleucel vs Standard of Care in Aggressive B-Cell Lymphoma
As reported in The New England Journal of Medicine by Bishop et al, the phase III BELINDA trial showed no improvement in event-free survival with second-line tisagenlecleucel vs standard of care including salvage chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) in patients ...
Daratumumab in Front-Line Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Questions Emerge From MAIA Trial
In the past decade, use of immunotherapy has arisen as a novel adjunct to multiple myeloma therapy. Daratumumab is the first anti-CD38 monoclonal antibody to be approved by the U.S. Food and Drug Administration (FDA), in November 2015, for use in treating relapsed or refractory multiple myeloma.1...
MAIA Trial: Daratumumab Added to Lenalidomide Plus Dexamethasone Improves Overall Survival in Transplant-Ineligible Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, of the Centre Hospitalier Universitaire de Lille, and colleagues, a prespecified interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to...
ORIENT-31: Novel Four-Drug Regimen Evaluated in EGFR-Mutated NSCLC
A four-drug combination of the anti–PD-1 antibody sintilimab, the bevacizumab biosimilar IBI305, plus pemetrexed and cisplatin chemotherapy significantly improved progression-free survival compared with chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with ...
Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumor
On November 22, 2021, sirolimus protein-bound particles for injectable suspension (albumin-bound) was approved for treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.1 Supporting Efficacy Data Approval was supported by findings in the...
Identifying Women With Triple-Negative Breast Cancer Who May Benefit From Pembrolizumab Plus Chemotherapy
Results of the phase III randomized KEYNOTE-355 trial showed that the addition of the PD-1 inhibitor pembrolizumab to investigator’s choice of first-line chemotherapy improved progression-free and overall survival in women with metastatic triple-negative breast cancer compared with placebo and...
NCCN Guidelines for Prostate Cancer: Panel Clarifies Role of Active Surveillance for Low-Risk Prostate Cancer
In October 2021, the National Comprehensive Cancer Network (NCCN) prostate caycer panel modified its guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines®]) for low-risk prostate cancer to remove the word “preferred option” for active surveillance, giving equal weight to...
I Don’t Know Why I Got Young-Onset Colorectal Cancer
Throughout my adolescence and early adulthood, I had been plagued with digestive issues, including bouts of gastritis and constipation, which seemed normal for me and wasn’t too concerning. But by the time I turned 30, in 2015, the acid reflux I had been experiencing became so frequent and...
Addition of First-Line Veliparib to Chemotherapy in Advanced Squamous Cell NSCLC: No Survival Benefit in Current Smokers, but Potential Benefit Among Biomarker-Selected Patients
In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, of Winship Cancer Institute, Emory University School of Medicine, and colleagues found that the addition of the PARP inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in...
Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
Solving the Conundrum of Young-Onset Colorectal Cancer
Although research so far has failed to uncover the root causes of the development of young-onset colorectal cancer, what is certain is that although colorectal cancer rates are declining in older adults, they are on a steady rise in people younger than age 50, especially those between the ages of...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
ZUMA-5 Trial: Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in The Lancet Oncology by Caron A. Jacobson, MD, and colleagues, the phase II ZUMA-5 trial showed that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, produced high rates of durable responses in patients with relapsed or refractory...
BELINDA Study: Second-Line Tisagenlecleucel Equivalent to Standard of Care for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
In an analysis of the phase III BELINDA trial presented by Bishop et al during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-6), the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was not found to improve event-free survival over the...
ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care in the second-line treatment of relapsed or refractory large B-cell lymphoma, according to...
Ivosidenib/Azacitidine vs Azacitidine Alone in Patients With Newly Diagnosed IDH1-Mutated AML
In the phase III AGILE trial, the combination of ivosidenib and azacitidine was found to be superior in treating newly diagnosed patients with IDH1-mutated acute myeloid leukemia (AML) compared to azacitidine alone in terms of event-free survival, the study’s primary endpoint. The combination also...
TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma
An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significantly improved event-free survival for patients with large B-cell lymphoma that persisted or returned...
Activity of Mosunetuzumab in Pretreated Patients With Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy, according to pivotal results of a phase I/II trial presented at the 2021 American Society of...
I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL
On October 1, 2021, the CD19-directed chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel was approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1 The product is available only through a restricted program under a Risk Evaluation ...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
The High Price of Pain
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...
Erudition and Assessment on the Longest War in the Modern Era
A little after noon on December 23, 1971, President Richard Nixon entered the White House state dining room. Before 137 esteemed guests from government, science, and industry, he signed the landmark National Cancer Act. It was, in short, a national commitment to conquer cancer. President Nixon...
Last Hug
“Good evening, doc; I wanted to check on you and update you on my mom” read the text message on a late Thursday afternoon. I recognized the sender; it was not uncommon for me to share my cell phone number with patients and their families. Having been a caretaker of my own parents’ medical needs, I...
Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early ...
Abemaciclib With Endocrine Therapy in Adjuvant Treatment of Early Breast Cancer
On October 12, 2021, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adults with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki67 score ≥ 20%, as determined by...
Asciminib for Philadelphia Chromosome–Positive Chronic Myeloid Leukemia
On October 29, 2021, the oral kinase inhibitor asciminib was granted accelerated approval for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase previously treated with at least two tyrosine kinase inhibitors and regular approval for adults with...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released
On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...
ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy
ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. The recommendations were published as two separate...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
Atezolizumab in Adjuvant Therapy for PD-L1–Positive NSCLC
On October 15, 2021, atezolizumab was approved for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 1% of tumor cells, as determined by a U.S. Food and Drug Administration...
Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
On November 17, 2021, the immunotherapeutic agent pembrolizumab was granted approval for adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions.1 Supporting Efficacy Data...
Adding Pembrolizumab to Chemotherapy Improves Overall and Progression-Free Survival in First-Line Treatment of Advanced Esophageal Cancer
As reported in The Lancet by Jong-Mu Sun, MD, of Samsung Medical Center, Sungkyunkwan University, Seoul, and colleagues, an interim analysis in the phase III KEYNOTE-590 trial has shown that the addition of first-line pembrolizumab to chemotherapy resulted in improved overall and progression-free...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
PALLAS Trial: Addition of Adjuvant Palbociclib to Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer
As reported at the 2021 San Antonio Breast Cancer Symposium (Abstract GS1-07) and simultaneously in the Journal of Clinical Oncology by Michael Gnant, MD, and colleagues, the final analysis of the phase III PALLAS trial has shown no invasive disease–free survival benefit with the addition of...
Expert Point of View: Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Comprehensive Breast Cancer Center, commented on the KEYNOTE-355 final analysis1 for The ASCO Post. “We now have a drug with full approval of the U.S. Food and Drug...
KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer
The final overall survival results from the KEYNOTE-355 study showed a statistically significant 27% reduction in the risk of death for patients with metastatic triple-negative breast cancer whose tumors were strongly positive for PD-L1, defined as a combined positive score (CPS) of at least 10 and ...
COVID-19 Vaccination: Patients With Multiple Myeloma May Lack T-Cell Response
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccination may also fail to mount a T-cell response, researchers from the Icahn School of Medicine at Mount Sinai have reported. This scenario seemed to be most common among patients actively treated with anti-CD38 and...
Addition of Cytoreductive Surgery to Platinum-Based Chemotherapy in Relapsed Ovarian Cancer
In a European Network of Gynecologic Oncology Trialists–Gynecologic Cancer Intergroup trial (DESKTOP III) reported in The New England Journal of Medicine, Philipp Harter, MD, PhD, and colleagues found that the addition of cytoreductive surgery to platinum-based chemotherapy improved overall...
